Caredx Inc (CDNA) valuation
Caredx P/E ratio history
Caredx trades at 36.6 times its earnings over the last twelve months and 69.0 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $18.84 | -$0.40 | n/m | — |
| Dec 31, 2024 | $21.41 | $0.93 | 23.0 | — |
| Dec 31, 2023 | $12.00 | -$3.54 | n/m | — |
| Dec 31, 2022 | $11.41 | -$1.44 | n/m | — |
| Dec 31, 2021 | $45.48 | -$0.59 | n/m | 125.5 |
| Dec 31, 2020 | $72.45 | -$0.40 | n/m | — |
| Dec 31, 2019 | $21.57 | -$0.52 | n/m | — |
| Dec 31, 2018 | $25.14 | -$1.33 | n/m | — |
| Dec 31, 2017 | $7.34 | -$2.21 | n/m | — |
| Dec 31, 2016 | $2.70 | -$2.57 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Caredx valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| CaredxCDNA | $4.52B | 36.6 | 69.0 | 9.1 |
| Dianthus TherapeuticsDNTH | $4.50B | — | — | — |
| ErascaERAS | $4.46B | — | — | — |
| Travere TherapeuticsTVTX | $4.69B | — | 14.8 | 7.9 |
| Livanova PlcLIVN | $4.34B | 23.3 | 17.5 | 3.0 |
| Integer HoldingsITGR | $4.30B | 42.2 | 18.9 | 2.4 |
| Adaptive BiotechnologiesADPT | $4.26B | — | — | 13.8 |
| Edgewise TherapeuticsEWTX | $4.18B | — | — | — |
| Indivior PharmaceuticalsINDV | $4.17B | 9.9 | 7.9 | 3.0 |
| Peer median | 23.3 | 16.1 | 3.0 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: CDNA financials · CDNA returns
No forecast, no recommendation. This page describes Caredx Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.